EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 38 / No 8-9 (Août-Septembre 2022) Med Sci (Paris), 38 8-9 (2022) 746-478 References
Issue
Med Sci (Paris)
Volume 38, Number 8-9, Août-Septembre 2022
Nos jeunes pousses ont du talent !
Page(s) 746 - 478
Section Partenariat médecine/sciences - Écoles doctorales - Masters
DOI https://doi.org/10.1051/medsci/2022116
Published online 12 September 2022
  1. McGuire MJ, Ishii M. Leptin dysfunction and Alzheimer’s disease: evidence from cellular, animal, and human studies. Cell Mol Neurobiol 2016 ; 36 : 203–217. [CrossRef] [PubMed] [Google Scholar]
  2. Chakrabarti S, Khemka VK, Banerjee A, et al. Metabolic Risk Factors of Sporadic Alzheimer’s Disease: Implications in the Pathology. Pathogenesis and Treatment. Aging Dis 2015 ; 6 : 282–299. [CrossRef] [Google Scholar]
  3. Khan S, Barve KH, Kumar MS. Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease. Curr Neuropharmacol 2020; 18 : 1106–25. [CrossRef] [PubMed] [Google Scholar]
  4. Lin X, Li H. Obesity: Epidemiology, Pathophysiology, and Therapeutics. Front Endocrinol 2021; 12 : 706978. [CrossRef] [PubMed] [Google Scholar]
  5. Lloret A, Monllor P, Esteve D, et al. Obesity as a Risk Factor for Alzheimer’s Disease: Implication of Leptin and Glutamate. Front Neurosci 2019 ; 13 : 508. [CrossRef] [PubMed] [Google Scholar]
  6. Zhao S, Kusminski CM, Elmquist JK, et al. Leptin: Less Is More. Diabetes 2020; 69 : 823–9. [CrossRef] [PubMed] [Google Scholar]
  7. Izquierdo AG, Crujeiras AB, Casanueva FF, et al. Leptin, Obesity, and Leptin Resistance: Where Are We 25 Years Later?. Nutrients 2019 ; 11 : 2704. [CrossRef] [Google Scholar]
  8. Van Doorn C, Macht VA, Grillo CA, et al. Leptin resistance and hippocampal behavioral deficits. Physiology & Behavior 2017 ; 176 : 207–213. [CrossRef] [PubMed] [Google Scholar]
  9. Bonda DJ, Stone JG, Torres SL, et al. Dysregulation of Leptin Signaling in Alzheimer Disease: Evidence for Neuronal Leptin Resistance. J Neurochem 2014 ; 128 : 162–172. [CrossRef] [PubMed] [Google Scholar]
  10. Flores-Dorantes MT, Díaz-López YE, Gutiérrez-Aguilar R. Environment and Gene Association With Obesity and Their Impact on Neurodegenerative and Neurodevelopmental Diseases. Front Neurosci 2020; 14 : 863. [CrossRef] [PubMed] [Google Scholar]
  11. Niedowicz DM, Reeves VL, Platt TL, et al. Obesity and diabetes cause cognitive dysfunction in the absence of accelerated β-amyloid deposition in a novel murine model of mixed or vascular dementia. Acta Neuropathol Commun 2014 ; 2 : 64. [CrossRef] [PubMed] [Google Scholar]
  12. Fuchsberger T, Martínez-Bellver S, Giraldo E, et al. Aβ Induces Excitotoxicity Mediated by APC/C-Cdh1 Depletion That Can Be Prevented by Glutaminase Inhibition Promoting Neuronal Survival. Sci Rep 2016 ; 6 : 31158. [CrossRef] [PubMed] [Google Scholar]
  13. Dietrich MO, Spuch C, Antequera D, et al. Megalin mediates the transport of leptin across the blood-CSF barrier. Neurobiol Aging 2008 ; 29 : 902–912. [CrossRef] [PubMed] [Google Scholar]
  14. Andreoli MF, Donato J, Cakir I, et al. Leptin resensitisation: a reversion of leptin-resistant states. J Endocrinol 2019 ; 241 : R81–R96. [CrossRef] [PubMed] [Google Scholar]
  15. Greco M, De Santo M, Comandè A, et al. Leptin-Activity Modulators and Their Potential Pharmaceutical Applications. Biomolecules 2021; 11 : 1045. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.